PCRX Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Pacira BioSciences (NASDAQ: PCRX)
›
Pacira BioSciences (NASDAQ: PCRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 825 employees.
The shares were at 36.48 USD on 16 November 2026, up 70.6% over 52 weeks. Its 52-week range is 18.80 USD to 36.67 USD, and it trades at the top of that range.
At a market capitalisation of 1.46B USD, it trades at 39.2 times trailing earnings and 10.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 59% for PCRX.
Pacira BioSciences reports return on equity of 1.0%, an operating margin of 4.0% and revenue down 1.6% year over year.
Its debt exceeds its cash by 44.70M USD, a debt-to-equity ratio of 0.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 33.57 USD is 8.0% below the current price. The next earnings report is expected on 25 February 2027.